Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEMPO-1: CRB-701 vs Standard of Care in Recurrent or Metastatic Oropharyngeal Squamous Cell Carcinoma
NCT07768189Phase 3Recruiting
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Sep 2026
- Primary completion
- Dec 2027
- Countries
- 14
01
Overview
A Phase 3 trial of CRB-701 in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Corbus Pharmaceuticals Holdings, Inc.. Started Sep 2026; status: recruiting.
02
Drugs
CRB-701
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT07768189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07768189.